TScan Therapeutics reports Q3 net loss of $16.2M and cash of $137.3M

TScan Therapeutics, Inc.

2022-Q3 EPS reported -$1.98 revenue$10,440,000

Net loss $16.2M vs $15.8M YoY; revenue $3.4M vs $2.4M YoY.
Cash and equivalents $137.3M; closed $60M debt facility with K2 HealthVentures, initial $30M drawn.
Phase 1 umbrella trial for TSC-100/101 enrolling; pre-IND meeting with FDA completed for solid tumors.
Plan IND submissions for MAGE-A1 TCRs by end 2022; HPV and PRAME INDs by H1 2023.
Virtual investor event Nov 14, 2022 to detail solid tumor clinical development plans.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TScan Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $3.4 million.

Period: the third quarter ended September 30, 2022
Revenue: $3.4 million
Result: reported results

Exact text from the filing

be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2024. Revenue for the third quarter ended September 30, 2022, was $3.4 million, compared to $2.4 million for the third quarter ended September 30, 2021 (2021 Quarter). This increase is due to research activities related to TScan’s collaboration agreement

View on SEC.gov

Browse all earnings releases →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023503

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.